Roche’s RoACTEMRA receives CHMP positive opinion in Europe for use in patients with RA
Roche announced that RoACTEMRA (tocilizumab, also known as ACTEMRA) has received a positive opinion from the Committee for Medicinal Products for Human Use for use in Europe in patients not previously treated with MTX with severe, active and progressive RA. July 28, 2014